Protein Misfolding and Aggregation in Proteinopathies: Causes, Mechanism and Cellular Response

Kurplus, 1983, Dynamics of proteins: Elements and function, Annu. Rev. Biochem., 52, 263, 10.1146/annurev.bi.52.070183.001403

Depta, 2022, Structure, function and small molecule modulation of intracellular sterol transport proteins, Bioorganic Med. Chem., 68, 116856, 10.1016/j.bmc.2022.116856

Kumar, 2009, Role of naturally occurring osmolytes in protein folding and stability, Arch. Biochem. Biophys., 491, 1, 10.1016/j.abb.2009.09.007

Houck, S.A., Singh, S., and Cyr, D. (2012). Ubiquitin Family Modifiers and the Proteasome, Springer.

Dobson, 2003, Protein folding and misfolding, Nature, 426, 884, 10.1038/nature02261

Stefani, 2003, Protein aggregation and aggregate toxicity: New insights into protein folding, misfolding diseases and biological evolution, J. Mol. Med., 81, 678, 10.1007/s00109-003-0464-5

Relini, 2013, Misfolding of amyloidogenic proteins and their interactions with membranes, Biomolecules, 4, 20, 10.3390/biom4010020

Zakariya, 2022, Biophysical Insight into Protein Folding, Aggregate Formation and its Inhibition Strategies, Protein Pept. Lett., 29, 22, 10.2174/0929866528666211125114421

Markossian, 2004, Protein folding, misfolding, and aggregation. Formation of inclusion bodies and aggresomes, Biochemistry, 69, 971

Hebert, 2007, In and out of the ER: Protein folding, quality control, degradation, and related human diseases, Physiol. Rev., 87, 1377, 10.1152/physrev.00050.2006

Fandrich, 2009, Structural polymorphism of Alzheimer and other amyloid fibrils, Prion, 3, 89, 10.4161/pri.3.2.8859

Bezsonov, 2013, Amyloidogenic peptides of yeast cell wall glucantransferase Bgl2p as a model for the investigation of its pH-dependent fibril formation, Prion, 7, 175, 10.4161/pri.22992

Dicara, 2008, Foot-and-mouth disease virus forms a highly stable, EDTA-resistant complex with its principal receptor, integrin αvβ6: Implications for infectiousness, J. Virol., 82, 1537, 10.1128/JVI.01480-07

Breydo, 2015, Structural, morphological, and functional diversity of amyloid oligomers, FEBS Lett., 589, 2640, 10.1016/j.febslet.2015.07.013

Jucker, 2013, Self-propagation of pathogenic protein aggregates in neurodegenerative diseases, Nature, 501, 45, 10.1038/nature12481

Payne, 2015, The utility of protein and mRNA correlation, Trends Biochem. Sci., 40, 1, 10.1016/j.tibs.2014.10.010

Georgescu, 2017, Structure of eukaryotic CMG helicase at a replication fork and implications to replisome architecture and origin initiation, Proc. Natl. Acad. Sci. USA, 114, E697, 10.1073/pnas.1620500114

Adamcik, 2018, Amyloid polymorphism in the protein folding and aggregation energy landscape, Angew. Chem. Int. Ed., 57, 8370, 10.1002/anie.201713416

Saarikangas, 2016, Protein aggregation as a mechanism of adaptive cellular responses, Curr. Genet., 62, 711, 10.1007/s00294-016-0596-0

Chernoff, 2007, Stress and prions: Lessons from the yeast model, FEBS Lett., 581, 3695, 10.1016/j.febslet.2007.04.075

Walker, 2006, Inducible proteopathies, Trends Neurosci., 29, 438, 10.1016/j.tins.2006.06.010

Chiesa, 2001, Prion diseases: What is the neurotoxic molecule, Neurobiol. Dis., 8, 743, 10.1006/nbdi.2001.0433

Bersuker, 2016, Protein misfolding specifies recruitment to cytoplasmic inclusion bodies, J. Cell Biol., 213, 229, 10.1083/jcb.201511024

Torrente, 2013, The metazoan protein disaggregase and amyloid depolymerase system: Hsp110, Hsp70, Hsp40, and small heat shock proteins, Prion, 7, 457, 10.4161/pri.27531

Alberti, 2021, Biomolecular condensates at the nexus of cellular stress, protein aggregation disease and ageing, Nat. Rev. Mol. Cell Biol., 22, 196, 10.1038/s41580-020-00326-6

Wickner, 2017, [PSI+] prion propagation is controlled by inositol polyphosphates, Proc. Natl. Acad. Sci. USA, 114, E8402, 10.1073/pnas.1714361114

Wickner, 2018, Anti-Prion Systems in Yeast and Inositol Polyphosphates, Biochemistry, 57, 1285, 10.1021/acs.biochem.7b01285

Mogk, 2017, Role of sHsps in organizing cytosolic protein aggregation and disaggregation, Cell Stress Chaperones, 22, 493, 10.1007/s12192-017-0762-4

Wickner, 2015, Yeast prions: Structure, biology, and prion-handling systems, Microbiol. Mol. Biol. Rev., 79, 1, 10.1128/MMBR.00041-14

Wickner, 2016, Yeast and fungal prions: Amyloid-handling systems, amyloid structure, and prion biology, Adv. Genet., 93, 191, 10.1016/bs.adgen.2015.12.003

Wickner, 2018, Yeast prions compared to functional prions and amyloids, J. Mol. Biol., 430, 3707, 10.1016/j.jmb.2018.04.022

Maury, 2009, The emerging concept of functional amyloid, J. Intern. Med., 265, 329, 10.1111/j.1365-2796.2008.02068.x

Christianson, 2022, Order through destruction: How ER-associated protein degradation contributes to organelle homeostasis, EMBO J., 41, e109845, 10.15252/embj.2021109845

Kramer, 2021, The proteasome: Friend and foe of mitochondrial biogenesis, FEBS Lett., 595, 1223, 10.1002/1873-3468.14010

Culver, 2022, A second chance for protein targeting/folding: Ubiquitination and deubiquitination of nascent proteins, BioEssays, 44, 2200014, 10.1002/bies.202200014

Gandhi, 2019, Protein misfolding and aggregation in neurodegenerative diseases: A review of pathogeneses, novel detection strategies, and potential therapeutics, Rev. Neurosci., 30, 339, 10.1515/revneuro-2016-0035

Soto, 2018, Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases, Nat. Neurosci., 21, 1332, 10.1038/s41593-018-0235-9

Mattoo, 2021, Idiopathic pulmonary fibrosis and systemic sclerosis: Pathogenic mechanisms and therapeutic interventions, Cell. Mol. Life Sci., 78, 5527, 10.1007/s00018-021-03874-y

Welsner, 2022, Effect of Triple Combination CFTR Modulator Therapy on Sleep in Adult Patients with Cystic Fibrosis, Respiration, 101, 766, 10.1159/000524773

Zhu, 2022, Alterations in Self-Aggregating Neuropeptides in Cerebrospinal Fluid of Patients with Parkinsonian Disorders, J. Park. Dis., 12, 1169

Jellinger, 2010, Basic mechanisms of neurodegeneration: A critical update, J. Cell. Mol. Med., 14, 457, 10.1111/j.1582-4934.2010.01010.x

Rao, 2004, Misfolded proteins, endoplasmic reticulum stress and neurodegeneration, Curr. Opin. Cell Biol., 16, 653, 10.1016/j.ceb.2004.09.012

Demeule, 2006, Where disease pathogenesis meets protein formulation: Renal deposition of immunoglobulin aggregates, Eur. J. Pharm. Biopharm., 62, 121, 10.1016/j.ejpb.2005.08.008

Dobson, C.M. (2004). Seminars in Cell & Developmental Biology, Elsevier.

2013, Systemic amyloidoses, Annu. Rev. Biochem., 82, 745, 10.1146/annurev-biochem-072611-130030

Ciechanover, 2006, The ubiquitin proteolytic system: From a vague idea, through basic mechanisms, and onto human diseases and drug targeting, Neurology, 66, S7, 10.1212/01.wnl.0000192261.02023.b8

Thomson, 2012, Autophagy and polyglutamine diseases, Prog. Neurobiol., 97, 67, 10.1016/j.pneurobio.2011.08.013

Aguzzi, 2010, Protein aggregation diseases: Pathogenicity and therapeutic perspectives, Nat. Rev. Drug Discov., 9, 237, 10.1038/nrd3050

Stefani, M. (2007). Protein Misfolding in Neurodegenerative Diseases, CRC Press.

Valastyan, 2014, Mechanisms of protein-folding diseases at a glance, Dis. Model. Mech., 7, 9, 10.1242/dmm.013474

Cortez, 2014, The therapeutic potential of chemical chaperones in protein folding diseases, Prion, 8, 197, 10.4161/pri.28938

Cohen, 2003, Therapeutic approaches to protein-misfolding diseases, Nature, 426, 905, 10.1038/nature02265

Lee, 2011, Molecular origins of surfactant-mediated stabilization of protein drugs, Adv. Drug Deliv. Rev., 63, 1160, 10.1016/j.addr.2011.06.015

Shakya, 2010, Stability of responsive polymer–protein bioconjugates, Prog. Polym. Sci., 35, 459, 10.1016/j.progpolymsci.2010.01.003

Chi, 2003, Physical stability of proteins in aqueous solution: Mechanism and driving forces in nonnative protein aggregation, Pharm. Res., 20, 1325, 10.1023/A:1025771421906

Pagel, 2015, Current strategies and findings in clinically relevant post-translational modification-specific proteomics, Expert Rev. Proteom., 12, 235, 10.1586/14789450.2015.1042867

Dasuri, 2013, Oxidative stress, neurodegeneration, and the balance of protein degradation and protein synthesis, Free. Radic. Biol. Med., 62, 170, 10.1016/j.freeradbiomed.2012.09.016

Stefani, 2010, Biochemical and biophysical features of both oligomer/fibril and cell membrane in amyloid cytotoxicity, FEBS J., 277, 4602, 10.1111/j.1742-4658.2010.07889.x

Evans, K.C. (1996). Conformational studies of the beta amyloid protein and in vitro models for the effects of apolipoprotein E on fibril formation in Alzheimer’s disease. [Ph.D. Dissertation, Massachusetts Institute of Technology].

Hipp, 2019, The proteostasis network and its decline in ageing, Nat. Rev. Mol. Cell Biol., 20, 421, 10.1038/s41580-019-0101-y

Bryngelson, 1995, Funnels, pathways, and the energy landscape of protein folding: A synthesis, Proteins Struct. Funct. Bioinform., 21, 167, 10.1002/prot.340210302

Veitshans, 1997, Protein folding kinetics: Timescales, pathways and energy landscapes in terms of sequence-dependent properties, Fold. Des., 2, 1, 10.1016/S1359-0278(97)00002-3

Boczko, 1995, First-principles calculation of the folding free energy of a three-helix bundle protein, Science, 269, 393, 10.1126/science.7618103

Mirny, 2001, Protein folding theory: From lattice to all-atom models, Annu. Rev. Biophys. Biomol. Struct., 30, 361, 10.1146/annurev.biophys.30.1.361

Finkelstein, 2018, 50+ years of protein folding, Biochemistry, 83, S3

Peydayesh, 2022, Amyloid-based carbon aerogels for water purification, Chem. Eng. J., 449, 137703, 10.1016/j.cej.2022.137703

Zhao, 2023, Programmable and low-cost biohybrid membrane for efficient heavy metal removal from water, Sep. Purif. Technol., 306, 122751, 10.1016/j.seppur.2022.122751

Etale, A., Onyianta, A.J., Turner, S.R., and Eichhorn, S.J. (2023). Cellulose: A Review of Water Interactions, Applications in Composites, and Water Treatment. Chem. Rev.

Ashrafian, 2021, Review on Alzheimer’s disease: Inhibition of amyloid beta and tau tangle formation, Int. J. Biol. Macromol., 167, 382, 10.1016/j.ijbiomac.2020.11.192

Bigi, 2022, Amyloid fibrils act as a reservoir of soluble oligomers, the main culprits in protein deposition diseases, BioEssays, 44, 2200086, 10.1002/bies.202200086

Chaturvedi, 2016, Protein misfolding and aggregation: Mechanism, factors and detection, Process Biochem., 51, 1183, 10.1016/j.procbio.2016.05.015

Alam, 2017, Protein aggregation: From background to inhibition strategies, Int. J. Biol. Macromol., 103, 208, 10.1016/j.ijbiomac.2017.05.048

Zaman, 2019, Protein misfolding, aggregation and mechanism of amyloid cytotoxicity: An overview and therapeutic strategies to inhibit aggregation, Int. J. Biol. Macromol., 134, 1022, 10.1016/j.ijbiomac.2019.05.109

Fefilova, A.S., Fonin, A.V., Vishnyakov, I.E., Kuznetsova, I.M., and Turoverov, K.K. (2022). Stress-Induced Membraneless Organelles in Eukaryotes and Prokaryotes: Bird’s–Eye View. Int. J. Mol. Sci., 23.

Aguzzi, 2013, Prions and lymphoid organs: Solved and remaining mysteries, Prion, 7, 157, 10.4161/pri.23536

Zhang, 2003, Multiple-peptide conjugates for binding β-amyloid plaques of Alzheimer’s disease, Bioconjugate Chem., 14, 86, 10.1021/bc025526i

Kosterin, 2014, Biochemical stages of amyloid-b peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer’s disease, Brain, 137, 887, 10.1093/brain/awt362

Mukherjee, 2017, Prion-like protein aggregates and type 2 diabetes, Cold Spring Harb. Perspect. Med., 7, a024315, 10.1101/cshperspect.a024315

Ciechanover, 2015, Degradation of misfolded proteins in neurodegenerative diseases: Therapeutic targets and strategies, Exp. Mol. Med., 47, e147, 10.1038/emm.2014.117

Sunde, 1997, The structure of amyloid fibrils by electron microscopy and X-ray diffraction, Adv. Protein Chem., 50, 123, 10.1016/S0065-3233(08)60320-4

Bucciantini, 2002, Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases, Nature, 416, 507, 10.1038/416507a

Glabe, 2006, Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis, Neurology, 66, S74, 10.1212/01.wnl.0000192103.24796.42

Iadanza, 2018, A new era for understanding amyloid structures and disease, Nat. Rev. Mol. Cell Biol., 19, 755, 10.1038/s41580-018-0060-8

Nilsson, 2004, Techniques to study amyloid fibril formation in vitro, Methods, 34, 151, 10.1016/j.ymeth.2004.03.012

Chen, 2011, Cellular strategies of protein quality control, Cold Spring Harb. Perspect. Biol., 3, a004374, 10.1101/cshperspect.a004374

Dubnikov, 2017, Protein quality control in health and disease, Cold Spring Harb. Perspect. Biol., 9, a023523, 10.1101/cshperspect.a023523

Gregersen, N., and Bross, P. (2010). Protein misfolding and cellular stress: An overview. Protein Misfolding Cell. Stress Dis. Aging, 3–23.

Amm, 2014, Protein quality control and elimination of protein waste: The role of the ubiquitin–proteasome system, Biochim. Et Biophys. Acta BBA Mol. Cell Res., 1843, 182, 10.1016/j.bbamcr.2013.06.031

Sabatini, 1982, Mechanisms for the incorporation of proteins in membranes and organelles, J. Cell Biol., 92, 1, 10.1083/jcb.92.1.1

Song, 2021, Quality control of the mitochondrial proteome, Nat. Rev. Mol. Cell Biol., 22, 54, 10.1038/s41580-020-00300-2

Baker, 2011, Mitochondrial protein quality control during biogenesis and aging, Trends Biochem. Sci., 36, 254, 10.1016/j.tibs.2011.01.004

Fox, 2012, Mitochondrial protein synthesis, import, and assembly, Genetics, 192, 1203, 10.1534/genetics.112.141267

Kuchler, 1992, Secretion of peptides and proteins lacking hydrophobic signal sequences: The role of adenosine triphosphate-driven membrane translocators, Endocr. Rev., 13, 499

Emanuelsson, 2000, Predicting subcellular localization of proteins based on their N-terminal amino acid sequence, J. Mol. Biol., 300, 1005, 10.1006/jmbi.2000.3903

Benyair, 2011, Protein quality control, retention, and degradation at the endoplasmic reticulum, Int. Rev. Cell Mol. Biol., 292, 197, 10.1016/B978-0-12-386033-0.00005-0

Barral, J.M., Broadley, S.A., Schaffar, G., and Hartl, F.U. (2004). Seminars in cell & developmental biology, Elsevier.

Vitale, 1999, The endoplasmic reticulum—Gateway of the secretory pathway, Plant Cell, 11, 615

Reggiori, 2022, ER-phagy: Mechanisms, regulation, and diseases connected to the lysosomal clearance of the endoplasmic reticulum, Physiol. Rev., 102, 1393, 10.1152/physrev.00038.2021

Nukala, V.N. (2007). Role of Calcium and Nitric Oxide Synthase (NOS) in Brain Mitochondrial Dysfunction. Ph.D. [Doctoral Dissertation, University of Kentucky].

Houry, 2001, Chaperone-assisted protein folding in the cell cytoplasm, Curr. Protein Pept. Sci., 2, 227, 10.2174/1389203013381134

Mogk, 2018, Cellular handling of protein aggregates by disaggregation machines, Mol. Cell, 69, 214, 10.1016/j.molcel.2018.01.004

Schwartz, 2009, Targeting proteins for destruction by the ubiquitin system: Implications for human pathobiology, Annu. Rev. Pharmacol. Toxicol., 49, 73, 10.1146/annurev.pharmtox.051208.165340

Haass, 2007, Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer’s amyloid β-peptide, Nat. Rev. Mol. Cell Biol., 8, 101, 10.1038/nrm2101

Jahn, 2008, Folding versus aggregation: Polypeptide conformations on competing pathways, Arch. Biochem. Biophys., 469, 100, 10.1016/j.abb.2007.05.015

Idiris, 2010, Engineering of protein secretion in yeast: Strategies and impact on protein production, Appl. Microbiol. Biotechnol., 86, 403, 10.1007/s00253-010-2447-0

2011, Oxidative stress in aging: Theoretical outcomes and clinical evidences in humans, Biomed. Aging Pathol., 1, 1, 10.1016/j.biomag.2011.03.001

Mosser, 2004, Molecular chaperones and the stress of oncogenesis, Oncogene, 23, 2907, 10.1038/sj.onc.1207529

Kriegenburg, 2012, Molecular chaperones in targeting misfolded proteins for ubiquitin-eins for ubiquitin–dependent degradation, FEBS J., 279, 532, 10.1111/j.1742-4658.2011.08456.x

McClellan, 2005, Protein quality control: Chaperones culling corrupt conformations, Nat. Cell Biol., 7, 736, 10.1038/ncb0805-736

Sherman, 2013, Less is more: Improving proteostasis by translation slow down, Trends Biochem. Sci., 38, 585, 10.1016/j.tibs.2013.09.003

Lottes, 2020, Homeostatic roles of the proteostasis network in dendrites, Front. Cell. Neurosci., 14, 264, 10.3389/fncel.2020.00264

Agashe, V.R., and Hartl, F.U. (2000). Seminars in Cell & Developmental Biology, Elsevier.

Zipfel, 2020, Matrix metalloproteinases as new targets in Alzheimer’s disease: Opportunities and challenges, J. Med. Chem., 63, 10705, 10.1021/acs.jmedchem.0c00352

Lannfelt, 2014, Amyloid β directed immunotherapy for Alzheimer’s disease, J. Intern. Med., 275, 284, 10.1111/joim.12168

Solomon, 2010, Immunotherapy for Alzheimer’s disease, Neuropharmacology, 59, 303, 10.1016/j.neuropharm.2010.04.004

Farias, 2011, Mechanisms of tau self-aggregation and neurotoxicity, Curr. Alzheimer Res., 8, 608, 10.2174/156720511796717258

Prokop, 2013, Microglia actions in Alzheimers disease, Acta Neuropathol., 126, 461, 10.1007/s00401-013-1182-x

Prinz, 2014, Microglia and brain macrophages in the molecular age: From origin to neuropsychiatric disease, Nat. Rev. Neurosci., 15, 300, 10.1038/nrn3722

Liu, 2022, Repurposing small-molecule drugs for modulating toxic protein aggregates in neurodegenerative diseases, Drug Discov. Today, 27, 1994, 10.1016/j.drudis.2022.04.003

Gouda, 2021, Emerging therapeutic strategies for Parkinson’s disease and future prospects: A 2021 update, Biomedicines, 10, 371, 10.3390/biomedicines10020371

Jain, 2009, Effect of trehalose on protein structure, Protein Sci., 18, 24, 10.1002/pro.3

Ghosh, 2021, From small molecules to synthesized polymers: Potential role in combating amyloidogenic disorders, ACS Chem. Neurosci., 12, 1737, 10.1021/acschemneuro.1c00104

Ajmal, 2017, Fibrillogenesis of human serum albumin in the presence of levodopa–spectroscopic, calorimetric and microscopic studies, Int. J. Biol. Macromol., 94, 301, 10.1016/j.ijbiomac.2016.10.025

Rousseau, 2006, Protein aggregation and amyloidosis: Confusion of the kinds, Curr. Opin. Struct. Biol., 16, 118, 10.1016/j.sbi.2006.01.011

Ajmal, 2016, Differential mode of interaction of ThioflavinT with native β structural motif in human α 1-acid glycoprotein and cross beta sheet of its amyloid: Biophysical and molecular docking approach, J. Mol. Struct., 1117, 208, 10.1016/j.molstruc.2016.03.081

Ajmal, 2017, H Biophysical insights into the interaction of hen egg white lysozyme with therapeutic dye clofazimine: Modulation of activity and SDS induced aggregation of model protein, J. Biomol. Struct. Dyn., 35, 2197, 10.1080/07391102.2016.1211552

Freyssin, 2018, Natural polyphenols effects on protein aggregates in Alzheimer’s and Parkinson’s prion-like diseases, Neural Regen. Res., 13, 955, 10.4103/1673-5374.233432

Caruana, 2011, Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds, FEBS Lett., 585, 1113, 10.1016/j.febslet.2011.03.046

Ngoungoure, 2015, Natural polyphenols binding to amyloid: A broad class of compounds to treat different human amyloid diseases, Mol. Nutr. Food Res., 59, 8, 10.1002/mnfr.201400290

Reddy, 2018, Protective effects of Indian spice curcumin against amyloid-β in Alzheimer’s disease, J. Alzheimer’s Dis., 61, 843, 10.3233/JAD-170512

Ferruzzi, 2009, Bioavailability of gallic acid and catechins from grape seed polyphenol extract is improved by repeated dosing in rats: Implications for treatment in Alzheimer’s disease, J. Alzheimer’s Dis., 18, 113, 10.3233/JAD-2009-1135

Yu, 2019, Gallic acid disruption of A β42 aggregation rescues cognitive decline of APP/PS1 double transgenic mouse, Neurobiol. Dis., 124, 67, 10.1016/j.nbd.2018.11.009

Mandel, 2008, Simultaneous manipulation of multiple brain targets by green tea catechins: A potential neuroprotective strategy for Alzheimer and Parkinson diseases, CNS Neurosci. Ther., 14, 352, 10.1111/j.1755-5949.2008.00060.x

Omar, 2017, Biophenols pharmacology against the amyloidogenic activity in Alzheimers disease, Biomed. Pharmacother., 89, 396, 10.1016/j.biopha.2017.02.051

Ferreira, 2011, Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation, FEBS Lett., 585, 2424, 10.1016/j.febslet.2011.06.030

Ayoub, 2022, Insights into the neuroprotective effects of Salvia officinalis L. and Salvia microphylla Kunth in the memory impairment rat model, Food Funct., 13, 2253, 10.1039/D1FO02988F

Li, 2021, Oral administration of resveratrol-selenium-peptide nanocomposites alleviates Alzheimers disease-like pathogenesis by inhibiting Aβ aggregation and regulating gut microbiota, ACS Appl. Mater. Interfaces, 13, 46406, 10.1021/acsami.1c14818

Bennett, 2019, Antisense oligonucleotide therapies for neurodegenerative diseases, Annu. Rev. Neurosci., 42, 385, 10.1146/annurev-neuro-070918-050501

Guo, 2014, Using antisense technology to develop a novel therapy for α-1 antitrypsin deficient (AATD) liver disease and to model AATD lung disease, Rare Dis., 2, 251

Papaefthymiou, 2022, Pancreatic cancer and oligonucleotide therapy: Exploring novel therapeutic options and targeting chemoresistance, Clin. Res. Hepatol. Gastroenterol., 46, 101911, 10.1016/j.clinre.2022.101911

Cload, 2009, Novel therapeutic modalities to address nondrugable protein interaction targets, Neuropsychopharmacology, 34, 142, 10.1038/npp.2008.115